Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Mr & Mrs Higgs have a powerful hoover! They are hoovering up about 2,000,000 shares a day now! Means less shares for those to buy on news! Only means one thing! This will rocket up on news as folks scramble for limited shares.
Outlook
· Unprecedent growth opportunities as pharma focuses funding on Covid-19 and respiratory diseases resulting the development of a strong pipeline of opportunities, for both Covid-19 and non-Covid-19 challenge studies along with the wider CRO services offered by the Group
· Strong pipeline of work to build H2 2020 revenue, targeting operational profitability by Q3 2020
· A further €2.5m of cost to be removed from the business in H2 2020
· Right management team in place, with a clear strategy, targeting the high margin pharma services sector, to deliver significant shareholder value
· A strategic review is underway in order to seek to monetise the 49% stake in Imutex and our other non-core investments such as the 62.5% in PrEP Biopharm and our 100% stake in an immunomodulator
Well done!
Took 2 attempts to buy some!
Great News! A top pharmaceutical vaccine development company has signed a major contract with Venn.
The start of things to come!
Open Orphan PLC Launch of Covid-19 Antibody Testing
04/06/2020 7:00am
UK Regulatory (RNS & others)
Marketing begins!
https://www.openorphan.com/covid-clear
I can see now why CF said monetisation of IMUTEX will be at least 3 months away!
That is the time it would take for them to complete a phase 3 challenge study for IMUTEX FLU-v.
Gosh if phase 3 is successful then the price tag for IMUTEX will be top dollar. Quote CF: “100m to 500m"!
What a one-off cash dividend win fall that would be.
Here is what the latest ScienceAlert published 30th May had to say about FLU-v
“3. A potential universal flu vaccine has passed an important set of clinical trials
The virus strains that cause influenza are shapeshifters, constantly moving beyond our ability to immunise against them - hence, we need annual flu shots to stay ahead of the disease. A 'universal' flu vaccine would give us a huge advantage in this race, and there's now a truly promising candidate on the cards.
The vaccine, called FLU-v, has successfully passed phase I and phase II clinical trials, demonstrating its safety in human subjects; it's been found to induce immune responses that last at least six months. We can't wait to see the results of the next phase of trials.”
https://www.sciencealert.com/can-t-deal-with-the-news-here-are-10-hopeful-stories-you-need-right-now/amp
Open Orphan
Four Core Revenue Generating Businesses
1. Hvivo – Challenge study business - world leader in testing vaccines & antivirals.
2. Hvivo - Laboratory Services & Testing – e.g. Covid antibody testing (new & about to launch).
3. Venn Sciences – Drug Development.
4. Open Orphan - Genomic Health Data Platform – Pharma Company access via annual subscription.
Resulting in four prospect pipelines of revenue business expanded with Covid opportunities.
1. Existing combined pipeline of near-term target contracts for Hvivo & Venn - £110m.
2. Substantial new pipeline of opportunities to develop Covid challenges studies - £35m to £70m.
3. Third party pharma Covid laboratory testing opportunities - £5m to £10m.
4. Rollout of Covid antibody testing £10 to £30m with further potential upside.
Total Prospect Revenue Income - £160m to £220m
Non-Core for monetisation
1. Imutex – Flu -v, phase III ready universal flue vaccine + phase II ready mosiquito saliva vaccine.
2. PrEPBiopharm – Viral prophylactic with expected use against COVID-19.
Let's hope I am surprised!
Great Presentation ! Pleased to have bought in today. Blue day tomorrow for sure! I would be surprised to see this hit 18p tomorrow.